• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Medication co-payment vouchers for P2Y12 inhibitors not associated with reduced major adverse cardiovascular events

byQasim HussainiandDaniel Fisher
January 12, 2019
in Cardiology, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for patients who had suffered a myocardial infarction (MI).

2. Medication vouchers were not associated with reduced major adverse cardiovascular events (MACE) in these patients.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Antiplatelet therapy, such as with P2Y12 inhibitors, is recommended for up to 1 year after myocardial infarction (MI). However, inability to afford the medication is often cited as a significant barrier to medication adherence. In this randomized controlled trial, patients with MI who received vouchers for a P2Y12 inhibitor had a slight increase in patient-reported medication persistence. However, there was no significant difference in 1-year major adverse cardiovascular events (MACE).

Overall, while this study suggests vouchers for P2Y12 inhibitors may not have a significant impact on cardiovascular health in post-MI patients, some limitations should be noted. For one, the study may not be generalizable to patients receiving P2Y12 inhibitors for other indications nor non-US populations. Further research is warranted in understanding the economics of providing vouchers as a public health intervention to improve outcomes.

Click to read the study in JAMA

RELATED REPORTS

Oral semaglutide reduces cardiovascular event rates in high-risk patients

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting

Relevant Reading: Medication adherence: A call for action

In-Depth [randomized controlled trial]: The Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS) was a multicenter and cluster randomized controlled trial that randomized 301 US hospitals, enrolling 11001 patients. Patients in the intervention group were given a voucher card for full payment prior to discharge that could be used to fill a generic (clopidogrel) or brand name (ticagrelor) P2Y12 inhibitor while patients in the control group did not receive a voucher. Persistence of P2Y12 inhibitor therapy and MACE, defined as the composite of all-cause death, recurrent MI, or stroke, at 1 year were the primary end points. Patient-reported persistence of P2Y12 therapy was higher in the voucher group (87.0% vs 83.8%, p < 0.001). However, there was no statistical difference in MACE at 1 year in both groups (10.2% vs 10.6%, p = 0.65).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: clopidogrelMACETicagrelor
Previous Post

The REACH trial: hydroxyurea safe and effective for sickle cell anemia in African children

Next Post

#VisualAbstract: Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children The PRIME Randomized Clinical Trial

RelatedReports

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Oral semaglutide reduces cardiovascular event rates in high-risk patients

June 5, 2025
Stent type may not be related to adverse cardiac events after surgery
Cardiology

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

February 17, 2025
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting

September 25, 2024
#VisualAbstract: Ticagrelor monotherapy reduces bleeding risk following percutaneous coronary intervention
StudyGraphics

#VisualAbstract: Ticagrelor monotherapy reduces bleeding risk following percutaneous coronary intervention

June 3, 2024
Next Post
#VisualAbstract: Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children The PRIME Randomized Clinical Trial

#VisualAbstract: Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children The PRIME Randomized Clinical Trial

Cognitive outcomes in older adults undergoing cardiovascular procedures unclear

The REGROUP trial: endoscopic and open vein-graft harvest associated with similar outcomes

#VisualAbstract: Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial

#VisualAbstract: Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early acetaminophen use reduces mortality risk in patients with sepsis-associated encephalopathy
  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.